Comparison of the upper gastrointestinal safety of Arthrotec® 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers

Clinical Therapeutics

Volumn 21, Issue 4, 1999, Pages 659-674

  Agrawal, Naurang M ^a   Caldwell, Jacques ^b   Kivitz, Alan J ^c   Weaver, Arthur L ^d   Bocanegra, Tomás S ^e   Ball, Julie ^e   Dhadda, Shobha ^e   Hurley, Steven ^e   Hancock, Larry ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Clinical Research Centers   (United States)

^c Altoona Center for Clinical Research   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e PFIZER INC   (United States)

Author keywords

Arthrotec; Diclofenac; Helicobacter pylori; Misoprostol; Nabumetone; Nonsteroidal antiinflammatory drugs; Osteoarthritis; Upper gastrointestinal ulcers erosions

Indexed keywords

ALUMINUM HYDROXIDE; ARTHROTEC; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COXITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; DYSPEPSIA; FEMALE; FLATULENCE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HIGH RISK POPULATION; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER;

EID: 0033050572     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88318-6     Document Type: Article

References (44)

1. McCarthy DM. Nonsteroidal antiinflammatory drug-induced ulcers: Management by traditional therapies. Gastroenterology. 1989;96:662-674.
2. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritis patients during chronic nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 1987;82: 1153-1158.
3. Roth SH, Bennett RE. Nonsteroidal antiinflammatory drug gastropathy: Recognition and response. Arch Intern Med. 1987;147:2093-2100.
4. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257-263.
5. Langman MJS. Epidemiologic evidence of the association between peptic ulceration and antiinflammatory drug use. Gastroenterology. 1989;96:640-646.
6. Graham DY, Agrawal NM, Roth S. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind, placebo-controlled trial. Lancet. 1988;ii:1277-1280.
7. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal anti-inflammatory drugs: The double-edged sword. Arthritis Rheum. 1995;38:5-18.
8. Ehsanullah RSB, Page MD, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: Controlled trial with ranitidine. BMJ. 1988;297:1017-1021.
9. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 1993;119: 257-262.
10. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol. 1993;88:1318-1323.
11. Langman MJS, Well J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343: 1075-1078.
12. Paulus HE. FDA Arthritis Advisory Committee meeting: Serious gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1988;31:1450-1451.
13. Labeling revisions for NSAIDs. FDA Drug Bull. 1989;19:3-4.
14. Fries JF. NSAID gastropathy: The second most deadly rheumatic disease? J Rheumatol. 1991;18:6-10.
15. Blower AL, Brooks A, Hill A, et al. Emergency admissions and deaths from upper gastrointestinal crises in relation to NSAID use. Gut. 1994;35:23-25.
16. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105(Suppl 1B): 31S-38S.
17. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123:241-249.
18. Koch M, Dezi A, Ferrario F, Capurso L. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury: A meta-analysis of randomized controlled clinical trials. Arch Intern Med. 1996; 156:2321-2332.
19. Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: A prospective, double-blind, multicenter study. Am J Gastroenterol. 1996;91:223-227.
20. Valentini M, Cannizzaro R, Poletti M, et al. Nonsteroidal antiinflammatory drugs for cancer pain: Comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. J Clin Oncol. 1995;13:2637-2642.
21. Elliott SL, Yeomans ND, Buchanan RR, Smallwood RA. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers: A placebo-controlled trial. Scand J Rheumatol. 1994;23:171-176.
22. Agrawal NM, Van Kerckhove HEJM, Erhardt LJ, Geis GS. Misoprostol coadministered with diclofenac for the prevention of gastroduodenal ulcers: A one-year study. Dig Dis Sci. 1995;40:1125-1131.
23. Karim A, Smith M. Biopharmaceutical profile of diclofenac-misoprostol combination tablet, Arthrotec. Scand J Rheumatol. 1992;Suppl 96:37-48.
24. Geis GS. Arthrotec: A therapeutic option in the management of arthritis. Eur J Rheumatol Inflamm. 1993;13:25-32.
25. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens. Ann Intern Med. 1995;123:344-350.
26. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 1993;153:2565-2571.
27. Altman RD. Criteria for classification of clinical osteoarthritis. J Rheumatol. 1991; 27(Suppl):10-12.
28. Cassagrande JT, Pike MC. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics. 1978;34:483-486.
29. Herson J, Wittes J. The use of interim analysis for sample size adjustment. Drug Inf J. 1993:27:1-7.
30. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: John Wiley & Sons; 1981.
31. Conover WJ. Practical Nonparametric Statistics. New York: John Wiley & Sons; 1980.
32. Rabinovitz M, Van Thiel DH. Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 1992;87:1696-1704.
33. Furst DE, Anderson W. Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1993;36:804-810.
34. Tarazi EM, Harter JG, Zimmerman HJ, et al. Sulindac associated hepatic injury: Analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology. 1993;104:569-574.
35. Hannequin JR. Efficacy of Arthrotec in the treatment of rheumatoid arthritis. Scand J Rheumatol. 1992;Suppl 96:7-14.
36. Doherty M. The efficacy of Arthrotec in the treatment of osteoarthritis. Scand J Rheumatol. 1992;Suppl 96:15-21.
37. Bolten W, Melo Gomes JA, Stead H, Geis GS. The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol. 1992; 31:753-758.
38. Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis. 1993;52:881-885.
39. McKenna F. Diclofenac/misoprostol: The European clinical experience. J Rheumatol. 1998;25(Suppl 51):21-30.
40. Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: A randomized, placebo controlled trial. J Rheumatol. 1998;25:1602-1611.
41. Malfertheiner P. Does Helicobacter pylori state affect nonsteroidal anti-inflammatory drug associated gastroduodenal pathology? Am J Med. 1998;104(Suppl):35S-40S.
42. Todd PA, Sorkin EM. Diclofenac sodium: A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Arthritis Rheum. 1986;29: 488-493.
43. Lanza FL. A double-blind study of the prophylactic effect of misoprostol on lesions of the gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Dig Dis Sci. 1986; 31(Suppl):131S-136S.
44. Aadland E, Fausa O, Vatn M, et al. Protection by misoprostol against naproxen-induced gastric mucosal damage. Am J Med. 1987;83(Suppl 1A):37S-40S.